Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting state Clear all
Completed Phase 1 Interventional

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

NCT03048344
View directory record Official record
Conditions
Advanced Hematological Disorders
Interventions
ORH-2014
Drug
Lead sponsor
Orsenix LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New York, New York • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

NCT01307657
View directory record Official record
Conditions
Healthy
Interventions
high fat meal
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 20, 2026, 1:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Physiology of Human Brown Adipose Tissue

NCT04352244
View directory record Official record
Conditions
Adipose Tissue, Brown, Adipose Tissue, Obesity
Interventions
Fat biopsy, Blood sampling, Blood sample for DNA analysis
Procedure · Diagnostic Test · Genetic
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

NCT05704556
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
7
States / cities
DeLand, Florida • Miami, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 20, 2026, 1:19 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

NCT05499260
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CB03-154, Placebo
Drug
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Levoketoconazole Food Effect Study in Healthy Subjects

NCT03768388
View directory record Official record
Conditions
Healthy Subjects
Interventions
levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

NCT05152485
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB104 Reference Formulation, BIIB104 Test Formulation
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Zelquistinel in Fasted or Fed State

NCT07099989
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Zelquistinel 3 mg, Zelquistinel 10 mg
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 20, 2026, 1:19 PM EDT
Active, not recruiting No phase listed Observational

Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

NCT01453660
View directory record Official record
Conditions
Germ Cell Cancer
Interventions
Endo-PAT2000 testing
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study of the Safety and PK Properties of Proellex®

NCT00749879
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Malaria: Relative Bioavailability and Food Effect of DSM265

NCT03637517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets

NCT01179646
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Drug
Lead sponsor
Kremers Urban Development Company
Industry
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

NCT00779259
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Theophylline 300mg, Quinine 648 mg, Theophylline 300 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

NCT05526742
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CKD-510 capsule (reference), CKD-510 tablet (test)
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

NCT00899470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of TP-05 in Healthy Subjects

NCT05138796
View directory record Official record
Conditions
Healthy
Interventions
TP-05 (lotilaner oral capsules), Placebo
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

NCT01899105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
lumacaftor, ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 20, 2026, 1:19 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Insulin Modulation of fMRI Connectivity in Healthy Adults

NCT02982551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

NCT00671970
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

NCT00983372
View directory record Official record
Conditions
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions
Colchicine, Diltiazem ER
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 20, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Sports Supplements on Blood Flow

NCT04278053
View directory record Official record
Conditions
Determine the Effects of Nitrosigine and Citrulline-malate on Flow-mediated Dilation Among Young Adults
Interventions
inositol-stabilized arginine silicate
Dietary Supplement
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 20, 2026, 1:19 PM EDT
Terminated Phase 1 Interventional Results available

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

NCT01378377
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pimasertib, Temsirolimus
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Rockland, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 20, 2026, 1:19 PM EDT